#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Gliflozins and kidney: Analyses of CREDENCE study


Authors: Marián Mokáň;  Peter Galajda
Authors‘ workplace: I. Interná klinika JLF UK a UN Martin
Published in: Forum Diab 2020; 9(2): 121-124
Category:

Overview

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, gliflozins are a new possibility of prevention of diabetic kidney disease (nephropathy) in patients with type 2 diabetes mellitus. Apart from glycemic control and low risk of hypoglycemia, gliflozins have been shown to provide significant cardiovascular and nephroprotective benefit. CVOT studies also confirmed the reduction of secondary renal composite by 44 % during the treatment by empagliflozin (study EMPA-REG OUTCOME), by 40 % in canagliflozin treatment (study CANVAS) and by 24 % in the case of dapagliflozin (study DECLARE TIMI-58). New study CREDENCE in diabetic patients with stage 2–3b of chronic kidney disease confirmed nephroprotective effect of canagliflozin in terms of reduction of primary renal composite about 30 %. In patients with diabetic kidney disease treatment with canagliflozin is associated with cardiovascular benefit with reduction of cardiovascular composite about 20 % and hospitalization for heart failure about 39 %. According to new extended SPC canagliflozin is indicated also as addition to standard treatment of patients with diabetic kidney disease in dose 100 mg/day.

Keywords:

gliflozins – diabetic kidney disease – nephroprotective benefit – sodium-glucose co-transporter-2 (SGLT2) inhibitors – study CREDENCE – type 2 diabetes mellitus


Sources

Martinka E, Tkáč I, Mokáň M (eds). Interdisciplinárne štandardy diagnostiky a liečby diabetes mellitus, jeho komplikácií a najvýznamnejších sprievodných ochorení. Forum Diab 2018; 7(Suppl 1): 5–153.

Martinka E, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu (2018). Vnitřní Lék 2018; 64(4): 405–426.

Mokáň M, Galajda P. Perspektívy liečby diabetes mellitus inhibítormi sodíko-glukózového kotransportéra-2. Diab Obez 2018; 18(35): 43–50.

Perlman A, Heyman SN, Matok I et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 2017; 27(12): 1108–1113.10. Dostupné z DOI: <http://dx.doi.org/1016/j.numecd.2017.10.011>.

[American Diabetes Association]. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018; 41 (Suppl 1): S86-S104. Dostupné z DOI: <https://doi.org/10.2337/dc18-S009>.

Zinman B, Wanner C, Lachin JM et al. [EMPAREG-OUTCOME Investigators]. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.

Neal B, Perkovic V, Mahaffey KW et al. [CANVAS Program Collaborative Group]. Canagliflozine and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.

Perkovic V, de Zeeuw D, Mahaffey KW et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018; 6(9): 691–704. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(18)30141–4>.

Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.

Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019; 7(8): 606–617. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(19)30180–9>.

Mende CW. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Curr Med Res Opin 2017; 33(3): 541–551. Dostupné z DOI: <http://dx.doi.org/10.1080/03007995.2016.1271779>.

Mokáň M, Okša A, Galajda P. Nefroprotektívny účinok gliflozínov u pacientov s diabetickou obličkovou chorobou – výsledky štúdie CREDENCE. Interná Med 2019; 19(9): 325–328.

Perkovic EV, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380 (24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

Kruger D, Valentine V. Canagliflozin for the treatment of diabetic kidney disease and implications for clinical practice: A narrative review. Diabetes Ther 2020; 11(6): 1237–1250. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–020–00826-w>.

Tkáč I. Výsledky štúdie CREDENCE (Canagliflozin in Renal Events in Diabetes with Established Nephropathy) a jej možné implikácie pre klinickú prax. Interná med 2019; 19 (4): 125–127.

Mahaffey KW, Jardine MJ, Bompoint S et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes and chronic kidney disease in primary and secondary cardiovascular prevention groups: results from the randomized CREDENCE trial. Circulation 2019; 140 (9):739–750. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007>.

Jardine MJ, Zhou Z, Mahaffey KW et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol 2020; 31(5): 1128–1139. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2019111168>.

Bakris G, Oshima M, Mahaffey KW et al. Canagliflozin slows declines in kidney function in people with baseline eGFR <30 mL/min/1.73 m2. American Society of Nephrology’s Kidney Week; 5–10. 11. 2019; Washington, DC. Poster TH-PO1202.

Jardine M, Zhou Z, Heesrpink H et al. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin According to Baseline Albuminuria: A CREDENCE Secondary Analysis. International Society of Nephrology world Congress, Abu Dhabi 26.-29. 3. 2020. Abstract SA-OR078.

Neuen BL, Mahaffey KW, Cannon CP et al. Effects of canagliflozin on cardiovascular, renal and safety outcomes by baseline loop diuretic use: Data from the CREDENCE trial. American College of Cardiology 69th Annual Scientific Session, Chicago 28.-30. 3. 2020. Poster.

Arnott C, Li JW, Cannon CP et al. The effects of canagliflozin on heart failureand cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. American College of Cardiology 69th Annual Scientific Session, Chicago 28.-30. 3. 2020. Poster.

Zhou Z, Jardine MJ, Li Q et al. Canagliflozin and stroke in diabetic kidney disease: Results from the CREDENCE trial. American College of Cardiology 69th Annual Scientific Session, Chicago 28.-30. 3. 2020. Poster.

Labels
Diabetology Endocrinology Internal medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#